Concepedia
Statistics
Publications
6
Citations
405
H-Index
Active since
2014
Affiliations
Ariadne Diagnostics (United States)(Current)
Takeda (Japan)
Dana-Farber Cancer Institute
NYU Langone Health
Theresa E. Baker is an author at Ariadne Diagnostics (United States) specializing in medicine, pharmacology, and oncology.
Publications per year
2014–2022
Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non–Small Cell Lung Cancer
Francois Gonzalvez, Sylvie Vincent, Theresa E. Baker et al. · Cancer Discovery · 2021 · 195 citations · Full text
Medicine, Oncology, Pharmacology +15
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors
Theresa E. Baker, Sujata Nerle, Justin R. Pritchard et al. · Oncotarget · 2015 · 81 citations · Full text
Medicine, Oncology, Pharmacology +14
Targeting <i>HER2</i> Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib
Han Han, Shuai Li, Ting Chen et al. · Cancer Research · 2021 · 57 citations · Full text
Medicine, Oncology, Pharmacology +16
Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models
Francois Gonzalvez, Xiaotian Zhu, Wei‐Sheng Huang et al. · Cancer Research · 2016 · 29 citations
Medicine, Oncology, Pharmacology +17
Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non–small cell lung cancer
Wei‐Sheng Huang, Feng Li, Yongjin Gong et al. · Bioorganic & Medicinal Chemistry Letters · 2022 · 25 citations · Full text
Medicine, Oncology, Pharmacology +13
1–5 of 6